Physician profile
Brooke A Ellinger
NPI 1275144099
$1,791.44
in general payments reported to CMS, 2019-2025
22 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $515 · 2022: $349 · 2023: $393 · 2024: $285 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $928.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $927.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $352.65 | 2021-2024 | |
| Astellas Pharma US INC | $274.33 | 2023-2025 | Veozah, Myrbetriq |
| Exeltis, USA INC. | $201.84 | 2021-2024 | Slynd |
| Amgen INC. | $200.62 | 2021-2025 | Evenity, Prolia, Prolia |
| Daiichi Sankyo INC. | $103.78 | 2021-2022 | |
| Therapeuticsmd, INC. | $86.91 | 2021 | |
| Renovia INC | $72.98 | 2021 | |
| Sage Therapeutics, LLC | $68.30 | 2022-2025 | Zurzuvae |
| Sumitomo Pharma America, INC. | $57.14 | 2024 | Myfembree |
| Coopersurgical, INC. | $47.02 | 2021-2023 | Summit Doppler |
| Bayer Healthcare Pharmaceuticals INC. | $43.76 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $39.46 | 2021-2023 | Gardasil 9 |
| Millicent US INC | $37.64 | 2025 | Femlyv |
| Scynexis, INC. | $31.85 | 2022 | |
| Avion Pharmaceuticals | $30.74 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $29.46 | 2022-2023 | Phexxi |
| Mayne Pharma Commercial LLC | $27.64 | 2022 | |
| Aspira Women'S Health INC | $26.49 | 2022-2023 | Ova1 |
| Hologic Sales and Service, LLC | $15.39 | 2024 | Aptima |
| Supernus Pharmaceuticals, INC. | $15.03 | 2025 | Qelbree |
| Mylan Pharmaceuticals INC. | $14.27 | 2021 | |
| Seqirus USA INC | $14.14 | 2024 | Fluad, Flucelvax |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brooke Ellinger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.